Innogen Pharmaceutical Reports No Share Capital Changes in April 2026; Public Float Remains Compliant

Bulletin Express05-06

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) submitted its Monthly Return for Equity Issuer covering the period ended 30 April 2026. Key points are as follows:

• Stable authorised share capital: The company’s authorised and registered share capital held steady at RMB 456.82 million, comprising 420.29 million H shares listed in Hong Kong and 36.53 million unlisted ordinary shares, all with a par value of RMB 1.

• No movements in issued shares: Issued H shares remained unchanged at 420.29 million. Unlisted shares also stayed flat at 36.53 million. The company held no treasury shares, and there were no repurchases, cancellations, allotments or other alterations during the month.

• Public float remains adequate: Innogen Pharmaceutical confirmed compliance with the Main Board’s minimum 25 % public float requirement for its H shares as at 30 April 2026.

• No outstanding equity-linked instruments: The filing records no share option schemes, warrants, convertibles or other arrangements that could lead to future share issuance.

The return was authorised by Joint Company Secretary Yang Dongyan and filed with Hong Kong Exchanges and Clearing Limited on 6 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181023653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 11:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181023653","market":"us","top_or_hot":-1,"title":"Innogen Pharmaceutical Reports No Share Capital Changes in April 2026; Public Float Remains Compliant","media":"Bulletin Express","content":"<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) submitted its Monthly Return for Equity Issuer covering the period ended 30 April 2026. Key points are as follows:</p>\n<p>• Stable authorised share capital: The company’s authorised and registered share capital held steady at RMB 456.82 million, comprising 420.29 million H shares listed in Hong Kong and 36.53 million unlisted ordinary shares, all with a par value of RMB 1.</p>\n<p>• No movements in issued shares: Issued H shares remained unchanged at 420.29 million. Unlisted shares also stayed flat at 36.53 million. The company held no treasury shares, and there were no repurchases, cancellations, allotments or other alterations during the month.</p>\n<p>• Public float remains adequate: Innogen Pharmaceutical confirmed compliance with the Main Board’s minimum 25 % public float requirement for its H shares as at 30 April 2026.</p>\n<p>• No outstanding equity-linked instruments: The filing records no share option schemes, warrants, convertibles or other arrangements that could lead to future share issuance.</p>\n<p>The return was authorised by Joint Company Secretary Yang Dongyan and filed with Hong Kong Exchanges and Clearing Limited on 6 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innogen Pharmaceutical Reports No Share Capital Changes in April 2026; Public Float Remains Compliant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnogen Pharmaceutical Reports No Share Capital Changes in April 2026; Public Float Remains Compliant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 11:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) submitted its Monthly Return for Equity Issuer covering the period ended 30 April 2026. Key points are as follows:</p>\n<p>• Stable authorised share capital: The company’s authorised and registered share capital held steady at RMB 456.82 million, comprising 420.29 million H shares listed in Hong Kong and 36.53 million unlisted ordinary shares, all with a par value of RMB 1.</p>\n<p>• No movements in issued shares: Issued H shares remained unchanged at 420.29 million. Unlisted shares also stayed flat at 36.53 million. The company held no treasury shares, and there were no repurchases, cancellations, allotments or other alterations during the month.</p>\n<p>• Public float remains adequate: Innogen Pharmaceutical confirmed compliance with the Main Board’s minimum 25 % public float requirement for its H shares as at 30 April 2026.</p>\n<p>• No outstanding equity-linked instruments: The filing records no share option schemes, warrants, convertibles or other arrangements that could lead to future share issuance.</p>\n<p>The return was authorised by Joint Company Secretary Yang Dongyan and filed with Hong Kong Exchanges and Clearing Limited on 6 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1181023653","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181023653","pubTimestamp":1778037794,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) submitted its Monthly Return for Equity Issuer covering the period ended 30 April 2026. Key points are as follows: • Stable...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"Innogen Pharmaceutical报告2026年4月股本没有变化；公众持股量保持合规","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) submitted its Monthly Return for Equity Issuer covering the period ended 30 April 2026. Key points are as follows:\n• Stable authorised share capital: The company’s authorised and registered share capital held steady at RMB 456.82 million, comprising 420.29 million H shares listed in Hong Kong and 36.53 million unlisted ordinary shares, all with a par value of RMB 1.\n• No movements in issued shares: Issued H shares remained unchanged at 420.29 million. Unlisted shares also stayed flat at 36.53 million. The company held no treasury shares, and there were no repurchases, cancellations, allotments or other alterations during the month.\n• Public float remains adequate: Innogen Pharmaceutical confirmed compliance with the Main Board’s minimum 25 % public float requirement for its H shares as at 30 April 2026.\n• No outstanding equity-linked instruments: The filing records no share option schemes, warrants, convertibles or other arrangements that could lead to future share issuance.\nThe return was authorised by Joint Company Secretary Yang Dongyan and filed with Hong Kong Exchanges and Clearing Limited on 6 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181023653","isCrawlerRequest":true}